News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fougera (AAA) Receives Approval For First Generic Sulfacetamide Sodium Topical Suspension USP 10% (Rx)


11/20/2006 9:53:32 AM

MELVILLE, N.Y., Nov. 17 /PRNewswire/ -- Specialty pharmaceutical manufacturer Fougera, a division of ALTANA Inc, announced today that it has received FDA approval to bring to market the first generic Sulfacetamide Sodium Topical Suspension USP 10% (Rx). The generic formulation compares to KLARON(R) by Dermik, whose patent has expired. The market for the brand name product was approximately $25 million in 2005.

(Photo: http://www.newscom.com/cgi-bin/prnh/20061117/NYF094 )

Sulfacetamide Sodium Topical Suspension USP 10% (Rx) is indicated for the topical treatment of acne. The Fougera product (NDC #0168-0382-04) is available in 118 mL (4 fl oz) bottles and began shipping today.

David Klaum, Senior Vice President, Commercial Business Operations, said, "Fougera will be first to market with generic Sulfacetamide Sodium Topical Suspension USP 10% (Rx), continuing our track record of receiving more topical generic FDA approvals than any other company during the past six years. The introduction of this product is another example of Fougera's continuing commitment to offer healthcare providers an ever expanding product portfolio to meet their patients' needs."

Fougera is a leading manufacturer and distributor of a wide range of multi-source topical steroids, antibiotics and antifungal products, as well as ophthalmic pharmaceuticals, in both prescription and over-the-counter dosage forms.

For more information on Sulfacetamide Sodium Topical Suspension USP 10% (Rx) or any other quality Fougera product, please call Fougera Customer Service at (800) 645-9833 or visit the company online at http://www.fougera.com.

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20061117/NYF094AP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comFougera

CONTACT: Angie Cecil of HLD/Blankman Public Relations, +1-516-536-6811, or+1-212-896-3926, acecil@hldblankman.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES